Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposal for Circadian Rhythms and Their Behavioral Outputs as Biomarkers in <i>DSM-6</i>: Response to Cuthbert et al.

The American journal of psychiatry·2026
Same author

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects.

The American journal of psychiatry·2026
Same author

Major depressive disorder is associated with reduced intrinsic connectivity between the bed nucleus of the stria terminalis and ventral striatum.

Journal of psychiatry & neuroscience : JPN·2026
Same author

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

JAMA psychiatry·2026
Same author

Mechanistic Underpinnings of Emotional Face Processing in Suicide Risk: Exploring the Moderating Effects of Cortisol on Neural Parameters Using Magnetoencephalography.

Psychiatric research and clinical practice·2026
Same journal

Mapping intrinsic neural timescale alterations in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

Progress in neuro-psychopharmacology & biological psychiatry·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

Lobna Ibrahim1, Nancy Diazgranados, David A Luckenbaugh

  • 1Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7-3445, Bethesda, MD 20892, USA.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|April 7, 2011
PubMed
Summary
This summary is machine-generated.

Ketamine effectively improved depressive symptoms in patients with major depressive disorder (MDD) who were resistant to electroconvulsive therapy (ECT). This suggests ketamine may be a viable treatment option for this challenging patient group.

More Related Videos

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is a significant public health concern.
  • Treatment-resistant MDD (TRD) poses a therapeutic challenge, often requiring novel interventions.
  • Electroconvulsive therapy (ECT) is a common treatment for TRD, but some patients do not respond.

Purpose of the Study:

  • To investigate the efficacy of ketamine in patients with TRD who previously did not respond to ECT.
  • To compare ketamine's effectiveness in ECT-resistant patients versus those who had not received ECT.

Main Methods:

  • A comparative study involving 17 ECT-resistant TRD patients and 23 non-ECT-exposed TRD patients.
  • All participants received a single open-label intravenous ketamine infusion (0.5 mg/kg).
  • Depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) at multiple time points pre- and post-infusion.

Main Results:

  • Significant improvement in depressive symptoms was observed in the ECT-resistant group at 230 minutes post-infusion (moderate effect size).
  • The non-ECT-exposed group showed a significantly larger improvement in depressive symptoms at 230 minutes (large effect size).

Conclusions:

  • Ketamine demonstrates potential in alleviating depressive symptoms in patients with MDD who are resistant to ECT.
  • Preliminary findings warrant larger studies to confirm ketamine's effectiveness compared to other TRD treatments.